74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Virbac SA
Closed
Sector Healthcare
311 2.47
Overview
Share price change
24h
Min
310
Max
311
Income | 95M |
|---|---|
Sales | 703M |
P/E Sector Avg | 18.112 73.394 |
Dividend yield | 0.43 |
Profit margin | 13.467 |
Employees | 5,459 |
EBITDA | 169M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +25.2 upside |
Dividend yield Sector Avg | 0.43% 3.09% |
|---|---|
Next Earnings | 13 Mar 2025 |
Market Cap | 2.6B |
|---|---|
Previous open | 308.53 |
Previous close | 311 |
News Sentiment
By Acuity
9%
91%
4 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Virbac SA Chart
Past performance is not a reliable indicator of future results.
Related News
Virbac SA Forecast
Price Target
By TipRanks
25.2% upside
12 Months Forecast
Average 390 EUR 25.2%
High 390 EUR
Low 390 EUR
Based on 1 Wall Street analysts offering 12 month price targets forVirbac SA - Dist in the last 3 months.
Sentiment
By Acuity
4 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.